TDC
INO icon

Thompson Davis & Co’s Inovio Pharmaceuticals INO Stock Holding History

Thompson Davis & Co’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-52
Closed -$6K – 1126
2016
Q2 		$6K Sell
52
-865
-94% -$105K 0.01% 755
2016
Q1 		$96K Buy
917
+896
+4,267% +$69.2K 0.14% 159
2015
Q4 		$2K Hold
21
– – ﹤0.01% 1020
2015
Q3 		$1K Hold
21
– – ﹤0.01% 1086
2015
Q2 		$2K Hold
21
– – ﹤0.01% 1080
2015
Q1 		$2K Hold
21
– – ﹤0.01% 1078
2014
Q4 		$2K Sell
21
-42
-67% -$5.13K ﹤0.01% 1100
2014
Q3 		$7K Buy
+63
New +$7.85K 0.01% 793

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Thompson Davis & Co's INO Position: Q3 2016 in Review

Thompson Davis & Co sold out of Inovio Pharmaceuticals (INO) in Q3 2016, closing a stake of 52 shares — an estimated $6K sold.

Thompson Davis & Co first reported a position in INO in Q3 2014 and held it in 8 quarters. The position peaked at $96K in Q1 2016. 125 funds tracked by Wall St. Rank hold INO as of Q3 2016.

  • Thompson Davis & Co reported no remaining Inovio Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 52 Inovio Pharmaceuticals shares in Q3 2016, an estimated $6K.
  • Thompson Davis & Co first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Thompson Davis & Co's Inovio Pharmaceuticals position peaked at $96K in Q1 2016.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2016.

Based on Thompson Davis & Co's 13F filing for Q3 2016, filed 8 Nov 2016.